A team of researchers for the J. Craig Venter Institute (JCVI), Synthetic Genomics Inc (SGI), Novartis Vaccines and Diagnostics, the Biomedical Advanced Research and Development Authority (BARDA), and Institut fur Virologie, Phillips Universitat, have published a study demonstrating a concept that could accurately construct robust synthetic vaccine viruses for influenza vaccine development in just four days and four hours. The method could help manufacturers pump out influenza vaccines vastly more rapidly in the event of a pandemic.
The research team was led by Philip R. Dormitzer, M.D., Ph.D., J. Craig Venter, Ph.D., JCVI and SGI, and Rino Rappuoli, Ph.D., Novartis, and was published in Science Translational Medicine. “We believe that synthetic genomic advances hold the key to transforming many industries and one of the most important will be in advanced vaccines that have the power to help prevent public health threats such as influenza pandemics,” said Dr. Venter, CEO and Founder of JCVI and SGI in a press release.
The researchers focused on overcoming these 3 technological barriers:
Speedy synthesis of DNA cassettes to produce influenza RNA genome segments
Improved accuracy of rapid gene synthesis by improving error correction technology
Increased yields of hemagglutinin (HA)
You can leave a comment in the box below, or on LinkedIn group discussion.
If you want to know more about strategy and innovation in vaccines, you might be interested in attending theWorld Vaccine Congress Asia 2013, 17-20 June 2013, Singapore. Want more from Vaccine Nation? Sign up to our newsletter for free here.